Gramón Bagó de Uruguay S.A.

What Gramón Bagó de Uruguay S.A. does

Gramón Bagó de Uruguay S.A. is a privately held Uruguayan pharmaceutical company founded in 1931 and headquartered in Montevideo, with over 90 years of continuous operation in the domestic market. The company researches, develops, manufactures, represents, and distributes pharmaceutical and healthcare products across all major therapeutic areas, including cardiology, oncology, neurology, dermatology, endocrinology, gastroenterology, pneumology, and general medicine. Its portfolio spans prescription pharmaceuticals (e.g., Linaglix, Zilobe, Xigduo XR, Xicane, Zoladex, Dioxaflex, Dolosedol), consumer health and OTC products, dermocosmetics (Bagóvit A, Bagóvit Solar, including a recently launched sunscreen line, plus represented Cetaphil), nutritional supplements (Simple, Inmunel, Genlif, B-GAN, Laxbene, Bagóvit Flex), and medical devices.

The company's operating backbone is an own GMP- and GLP-certified production plant located in Uruguay, paired with an integrated management system certified to ISO 9001 (quality), ISO 14001 (environmental), ISO 45001 (occupational health and safety), and ISO 27001 (information security), with ISO 37001 (anti-bribery) and ISO 37301 (anti-corruption) certifications in process. Beyond manufacturing, Gramón Bagó combines its own brands with represented multinational brands (e.g., Cetaphil, Zoladex via AZ Med) and reaches the Uruguayan market through a nationwide pharmacy network, direct sales into hospitals and healthcare institutions, and an export business covering select regional markets. Revenue is not publicly disclosed, the company is private, and there is no evidence of external funding, parent ownership, or M&A activity in the input data; a consistently active product launch cadence (2023-2025) and ongoing certification investments indicate the company is investing organically in portfolio breadth, regulatory standing, and geographic reach.

Name

Gramón Bagó de Uruguay S.A.

Legal name

Gramón Bagó de Uruguay S.A.

Website

https://gramonbago.com.uy

Company type

Private

Founded year

1931

Operating status

Operating

Headcount range

1–10 employees

Short description

Gramón Bagó is a Uruguayan pharmaceutical company founded in 1931 that researches, manufactures, represents, and distributes prescription medicines, OTC products, dermocosmetics, and nutritional supplements across all therapeutic areas, supplying pharmacies, hospitals, and export markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Pharmaceutical manufacturing
• Prescription medications
• Dermocosmetics skincare
• Nutritional supplements
• OTC consumer health

Headquarters

HQ city

Montevideo

HQ country

Uruguay

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Research, development, production, representation and distribution of pharmaceutical products across all therapeutic areas including prescription medications, OTC products, dermocosmetics, nutritional supplements, and medical devices

Distribution channels3 records

Marketing channels3 records

Core offering

Gramón Bagó de Uruguay S.A. researches, develops, manufactures, represents, and distributes pharmaceutical products across all therapeutic areas for the Uruguayan market. Its portfolio spans prescription medications (e.g., oncology, neurology, diabetes, psychiatry, anti-inflammatory treatments), over-the-counter products, dermocosmetics (Bagóvit, Cetaphil), nutritional supplements, and represented international brands, produced in its own GMP- and GLP-certified manufacturing facility.

Product overview

Gramón Bagó de Uruguay S.A. is a pharmaceutical company with over 90 years of leadership in the Uruguayan market that researches, develops, produces, represents, and distributes effective, reliable, and accessible products across all therapeutic areas for health care. The portfolio includes prescription medications (Productos Éticos), consumer health care products, dermocosmetics (Bagóvit A, Bagóvit Solar, Cetaphil), nutritional supplements (Simple, Inmunel, Genlif, B-GAN), and prescription pharmaceuticals (Zoladex, Zilobe, Linaglix, Xigduo XR, Xicane, Ibutrón, Dioxaflex, Dolosedol). The company operates with its own GMP-certified production plant and distributes both locally manufactured products and internationally represented brands.

Differentiator

Problem solved

Functional benefit

Products and services

• Bagóvit A
• Bagóvit Solar
• Bagóvit Flex
• Bagóvit Protectores Solares
• Cetaphil
• Laxbene®
• B-GAN® 1000
• Ibutrón®
• Linaglix (linagliptina 5 mg)
• INTILAC®
• Inmunel®
• Genlif®
• Zoladex
• Zilobe
• Xigduo XR
• Xicane®
• Dioxaflex
• Dolosedol
• Simple

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• AZ MedminorOthers · 1 January 2025AZ Med is a distribution partner for pharmaceutical products including Zoladex, providing access to oncology treatments in the Uruguayan market

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Gador: Argentine pharmaceutical company with own manufacturing, broad therapeutic coverage and export-oriented model. Comparable as a mid-sized, vertically integrated LATAM pharma manufacturer with branded and generic products.
• Laboratorios Bagó: Argentina-based pharmaceutical group with a similar brand heritage (Bagó) operating across prescription, OTC and consumer health across LATAM. Closest comparable by name, scope, and product mix including the Bagóvit dermocosmetics franchise.
• Roemmers: Argentina-headquartered pharma group manufacturing and distributing branded and generic medicines across multiple therapeutic areas. Comparable in scope, LATAM regional model and presence across prescription plus consumer health.

Regional players

• Megalabs: LATAM pharmaceutical group with manufacturing and commercial operations across the region including branded generics, specialty and consumer health. Comparable as a regional pharma competitor operating in similar therapeutic categories.

Broad incumbents

• Sanofi Uruguay: Multinational pharmaceutical company with local commercial operations in Uruguay, including specialty and consumer health (e.g., dermatology). Comparable as a multinational incumbent competing in the same Uruguayan channels.
• Bayer Uruguay: Multinational pharma with established direct commercial operations in Uruguay, particularly in specialty care. Comparable as a competitor operating in the same Uruguayan prescription market with overlapping therapeutic coverage.
• Eurofarma: Brazilian pharmaceutical company with broad prescription, OTC and generics portfolio and growing LATAM presence. Comparable as a larger LATAM incumbent with full vertical integration and export footprint.
• Pfizer Uruguay: Multinational pharmaceutical company with a Uruguay presence across primary care and specialty therapeutics. Comparable as a multinational competitor operating in the same Uruguayan prescription and hospital channels.
• EMS Pharma: Largest Brazilian pharmaceutical company by units, strong in generics and branded generics with growing international operations. Comparable as a broad LATAM incumbent competing in similar therapeutic and consumer health categories.
• Teva Pharmaceutical: Global leader in generic and specialty pharmaceuticals with commercial reach across LATAM. Comparable as a broad incumbent whose generics and specialty portfolio compete in overlapping categories (e.g., neurology, multiple sclerosis, oncology).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gramón Bagó de Uruguay S.A.